Antineutrophil cytoplasmic antibody-associated vasculitis: insights into relapse risk and future management directions
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has a relapsing-remitting course and, even with the availability of effective maintenance therapies such as rituximab, relapse rates remain high. Relapse is associated with the accr…